SeaGen Inks Abbott Deal

other

▤ Summary

SeaGen Inks Abbott Deal Xconomy Seattle — Seattle Genetics (NASDAQ: SGEN), said today it will get an $8 million upfront payment from Abbott Laboratories in exchange for the right to use technology that links targeted antibodies to toxins that make them more potent drugs.Abbott (NYSE: ABT) has gotten a license to use the Seattle Genetics technology against one molecular target on cancer cells.Seattle Genetics is eligible to receive as much as $200 million in milestone payments through the deal, plus royalties on product sales.Seattle Genetics now has licensed its antibody linking technology to 11 different organizations.

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies